Get started
Author

Laura Graham

ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following prior therapies for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
2026 · Rohit K. Jain, Yuanquan Aaron Yang, et al. · Journal of Clinical Oncology · 2
PDF
Germline whole-exome sequencing reveals FOXP3 -related gene variants conferring urinary cancer susceptibility and associated with immune escape
2025 · Bing-Jian Feng, Wendy Kohlmann, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.
2024 · Justine Panian, Nicholas Henderson, et al. · Journal of Clinical Oncology · 1
Clinical implications of Wnt signaling alterations in patients (pts) with advanced prostate cancer (aPC).
2023 · Amanda Broderick, Jinju Li, et al. · Journal of Clinical Oncology · 1
PDF
ADC Target Signatures in Urothelial Carcinoma: A Transcriptomic Framework for Precision Therapy
2026 · Edwin Lin, Feng Bing-Jian, et al. · International Journal of Cancer Care and Delivery
PDF
SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial Carcinoma
2026 · Bing-Jian Feng, Kaniz Fatema, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
DNA Methyltransferase Inhibitors, Decitabine and Guadecitabine Overcome Immune-Checkpoint Blockade Resistance and Achieve Tumor Regression in the E0771 and 4T1 Murine Models of Triple-Negative Breast Cancer
2026 · S. Jennifer Wang, Carolyn Haynes, et al. · Cancers
Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy
2026 · Edwin Lin, Bing-Jian Feng, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Genomic predictors of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): A real-world analysis from the PROMISE registry.
2026 · Peter D. Zang, Nicholas Henderson, et al. · Journal of Clinical Oncology
Real-world clinical outcomes by HER2 expression in locally advanced/metastatic urothelial carcinoma (la/mUC): Results from the global SGNDV-003 retrospective study.
2026 · Vadim S. Koshkin, Christine Abraham Jaillon, et al. · Journal of Clinical Oncology
Pd27-06 Novel Androgen Receptor Recurring Splice Junctions in Prostate Cancer Predicts Response to Abiraterone and Overall Survival in Metastatic Prostate Cancer
2026 · Kendrick Yim, Alyssa Obermeyer, et al. · The Journal of Urology
Ip77-26 Decoding the Tumor Ecosystem: Rna-seq Profiling Reveals Microbiome–tme Coupling in Bladder Cancer
2026 · John L. Pfail, Rachel Passarelli, et al. · The Journal of Urology
Insulin pathway changes in localized prostate cancer: A multi-institutional analysis.
2026 · Evan Adler, Anwaruddin Mohammad, et al. · Journal of Clinical Oncology
PDF
ADC target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy.
2026 · Edwin Lin, Feng Bing-Jian, et al. · Journal of Clinical Oncology
Unraveling the gene expression signatures with associated clinical outcomes in papillary renal cell carcinoma.
2024 · Juan Antonio Raygoza Garay, Samragnyi Madala, et al. · Journal of Clinical Oncology
Association of prior poly(ADP-ribose) polymerase (PARP) inhibitor therapy with response to 177Lu-PSMA-617 (LuPSMA) in men with DNA damage repair (DDR) mutations.
2024 · Ruben Raychaudhuri, George Mo, et al. · Journal of Clinical Oncology
PDF
Utilizing a best practice advisory (BPA) to increase pneumocystis jirovecii pneumonia (PJP) prophylaxis prescribing for patients with cancer on high dose corticosteroids.
2023 · Megan Spradlin, Sarah Rhoads, et al. · JCO Oncology Practice
PDF
Transdermal square-wave testosterone therapy: A pilot trial in metastatic castration-resistant prostate cancer.
2023 · Nellowe Candelario, Andrew Nicklawsky, et al. · Journal of Clinical Oncology
PDF
Works count: 18
Citation count: 5
H-index: 1
I10-index:
Year
Topic
Type